https://doi.org/10.1016/s0140-6736(22)00688-2
J
Jarosław Leszczyszyn
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
44
Papers
1.5K
Citations
15
h-index
20
i10-index
Jarosław Leszczyszyn is an academic researcher. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Gallbladder and Bile Duct Disorders. The author has an h-index of 15, co-authored 38 publications.
ORCID: 0000-0001-9134-2070Papers by this author
worksUstekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
2022 · The Lancet · 277 citations
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
2021 · Gastroenterology · 216 citations
https://doi.org/10.1053/j.gastro.2021.02.068
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Gastroenterology · 88 citations
https://doi.org/10.1053/j.gastro.2023.08.038
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2024 · The Lancet · 76 citations
https://doi.org/10.1016/s0140-6736(24)01762-8
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · The Lancet · 67 citations
https://doi.org/10.1016/s0140-6736(24)01927-5
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2023 · The Lancet. Gastroenterology & hepatology · 61 citations
https://doi.org/10.1016/s2468-1253(23)00318-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat